BioBlast Pharma

40 articles about BioBlast Pharma

• Bioblast Pharma Reports Third Quarter 2017 Financial Results

  11/2/2017

  The company announced financial results for the third quarter ended September 30, 2017.

• BioBlast Pharma Announces Effectiveness Of Five To One Reverse Split

  9/25/2017

• BioBlast Pharma Reports Second Quarter 2017 Financial Results

  8/7/2017

• Israel's Struggling BioBlast Pharma Seeks Strategic Alternatives Including Partnership And Possible M&A

  6/6/2017

• BioBlast Pharma Reports First Quarter 2017 Financial Results

  5/30/2017

• BioBlast Pharma Announces Plans In Response To Nasdaq Notifications Regarding Stockholders’ Equity And Minimum Bid Requirements

  4/18/2017

• BioBlast Pharma Announces Termination Of Securities Offering

  4/7/2017

• BioBlast Pharma Provides Research And Development Update

  12/9/2015

• BioBlast Pharma Reports Third Quarter Financial Results

  11/17/2015

• BioBlast Pharma Strengthens Leadership Team And Announces Key Organizational Changes

  11/16/2015

• BioBlast Pharma Announces Website Availability Of Webcast Related To Key Opinion Leader Meeting In Oculopharyngeal Muscular Dystrophy (OPMD)

  11/9/2015

• BioBlast PharmaTo Host Conference Call & Webcast On Tuesday, October 27 To Discuss Interim Results From HOPEMD Phase II Clinical Study Of Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD)

  10/27/2015

• BioBlast Pharma Announces Positive Interim Results From HOPEMD Phase II Clinical Study Of Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD)

  10/27/2015

• BioBlast Pharma Augments Leadership Team

  10/9/2015

• BioBlast Pharma Announces Appointment Of Tom Dubin, Former Alexion SVP & Chief Legal Officer, To The Board Of Directors

  9/16/2015

• BioBlast Pharma Granted Patent From USPTO For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA)

  9/14/2015

• BioBlast Pharma Augments Leadership Team And Establishes U.S. Headquarters In New Haven, Connecticut

  9/10/2015

• BioBlast Pharma To Present At Rodman & Renshaw Conference On September 10

  9/8/2015

• BioBlast Pharma Reports Second Quarter Financial Results

  8/21/2015

• BioBlast Pharma Receives Orphan Drug Designation From The European Commission (EC) For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA)

  6/29/2015